Antibiotic Gets Stronger Alarmist Admonishing
The FDA today ordered stronger warnings of potentially deadly liver failurewith the antibacterial Ketek (telithromycin).
Ketek is acclimatized to action adroit bacterial sinusitis, mild to moderate pneumonia, and adroit deepening of chronic bronchitis.
The stronger admonishing is based on the FDA's assay of Ketek's postmarketing adverse blow reports. Those annual actualization 12 cases of adroit alarmist aborticide -- four of which were fatal; a fifth adapted a alarmist transplant. There were also an added 23 cases of adroit alarmist injury.
In some cases, those alarmist problems started "even afterwards a few doses of the Ketek and progressed rapidly," Gerald DalPan, MD, told reporters in a teleconference. DalPan works in the FDA's Office of Epidemiology and Surveillance Center for Biologic Evaluation and Research.
Ketek's new assuming will advise doctors and patients to watch anxiously for signs and amore of alarmist chafe while demography Ketek and "to discontinue the biologic promptly if any signs or amore of alarmist chafe are to develop," the FDA's John Jenkins, MD, told reporters in the teleconference. Jenkins directs the Office of New Drugs at the FDA's Center for Biologic Evaluation and Research.
DalPan says the bulk of arise alarmist challenge was 23 out of 10 million prescriptions. That's an appraisement based on arise cases and dispensed prescriptions, not an blow rate, because there may be unreported cases, DalPan says.
Additional Warning
Ketek's new assuming will aswell calendar that there acquire been belletrist of fatal worsening of the neuromuscular condition, myasthenia gravis. The FDA knows of three arise deaths in myasthenia gravis patients demography Ketek, according to DalPan.
DalPan says the myasthenia gravis patients who died while demography Ketek were in their 70s and 80s and were demography Ketek for respiratory infection. The myasthenia gravis deaths are "completely separate" from the liver problems arise with Ketek, DalPan says.
When the FDA acclimatized Ketek in April 2004, the drug's labeling included precautions about alarmist chafe and attainable deepening of myasthenia gravis, as with added drugs in its class.
"The annual about alarmist anguish on the assuming has been upgraded from a precaution to a admonishing and the assuming has about been able to include a description of the sometimes accelerated admission … and the severity of the liver injury," DalPan says.
The drug's anterior admonishing about myasthenia gravis did not acceptance death risk because no calamitous cases were accustomed at that time.
Ketek is bogus by Sanofi Aventis. Sanofi Aventis is a WebMD sponsor.